This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Opko Health, Inc.
11/4/2026
Good day and welcome to the Opco Health Third Quarter 2026 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star and then two. Please note this event is being recorded. I would now like to turn the conference over to Vivian Cervantes, Alliance Advisors, Investor Relations. Please go ahead.
Thank you, Operator. Good afternoon, everyone. Thank you for joining us in today's call to discuss Opco Health's financial results for the third quarter of 2026. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking and as such are subject to risks and uncertainties that could materially affect the company's results. Those forward-looking statements include without limitation the various risks described in the company's SEC filings including the annual report on Form 10-K for the year ended December 31st, 2025. Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast November 4, 2026. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Regarding the format of today's call, Dr. Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Dr. Elias Zerhouni, President and Vice Chairman, will then review OPCO's pipeline and business. After that, Adam Logal, Opco's Chief Financial Officer will review the now LabCorp transaction, the company's third quarter financial results, and its outlook. We will then open the line to the call for questions. I'd now like to turn the call off over to Dr. Frost.
Good afternoon, and thank you for joining us today. The LabCorp transaction marks a defining moment for Opco. Once closed, it will complete our exit from clinical laboratory services sharpen our focus and allow our management attention, our people, and our capital to focus on biotech innovation and our global products business. Adam will provide the transaction and financial details later. This reflects the approach we have applied throughout our proposed history. Build differentiated businesses and assets, validate their value, monetize them at the right time, and redeploy capital into our highest return opportunities. Going forward, Opco is centered on two continuing businesses. Innovative biotech brings together MODEX and Opco Biologics with a broad portfolio across oncology, immunology, infectious disease and endocrinology. Global products include Rialdi, and our international pharmaceutical operations with established commercial capabilities and recurrent cash flow. The third quarter was one of steady execution across our pipeline. MODX expanded its clinical activity, completed enrollment in the planned phase one cohort for MDX 2301, and continue advancing our differentiated in vivo CAR-T platform toward the clinic. Elias will discuss that progress. Collaborations with Merck, Regeneron, Interrobio, and BARDA continue to add scientific capability, external validation, and non-dilutive support, while Angenwa, Rialdi, and our international operations contribute to the strength of the business. During the quarter, we purchased over 7 million shares of our common stock. leaving over 80 million of our 220 million authorization for additional purposes. With that, I'll turn the call over to Elias for a view of our pipeline and business.
You're reading a preview of the OPK Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing